TLSA Tiziana Life Sciences |
$2.07
+5.1% |
+8.9%
 |
ECTRIMS
Pathogenesis of neuroinflammatory diseases
|
|
9/25/2025 - Presentation
Immunic, Inc announced the presentation of key data in an oral and four poster presentations, includ…
Full Summary
|
MRK Merck & Co., Inc. |
$77.70
-2.5% |
-8.7%
 |
EV-303
For Certain Patients with Muscle-Invasive Bladder Cancer
|
|
9/25/2025 - Highlights
Pfizer Inc will highlight data across its extensive Oncology portfolio at the European Society for M…
Full Summary
|
BMY Bristol Myers Squibb |
$43.45
-1.6% |
-8.0%
 |
Deucravacitinib
Moderate to severe plaque psoriasis
|
|
9/25/2025 - Expansion
Bristol Myers Squibb announced an expansion of its direct-to-patient offerings, providing eligible …
Full Summary
|
ACIU AC Immune |
$2.91
+6.6% |
+38.6%
 |
ACI-35.030
Alzheimer’s Disease (AD)
|
|
9/25/2025 - Publication
AC Immune SA announced the peer-reviewed publication in eBioMedicine of results from the completed P…
Full Summary
|
LPTX Leap Therapeutics |
$0.35
+12.6% |
+16.8%
 |
DKN-01
Advanced gynecological malignancies
|
|
9/25/2025 - Results
Leap Therapeutics, Inc announced it will present the final clinical results from Part B of the DeF…
Full Summary
|
CAPR Capricor Therapeutics |
$6.52
+5.3% |
+0.8%
 |
deramiocel
For the treatment of Duchenne muscular dystrophy (DMD)
|
BLA
|
9/25/2025 - Provided Update
Capricor Therapeutics announced a regulatory update for its Biologics License Application (BLA) for …
Full Summary
|
MDWD MediWound |
$17.70
-1.8% |
+5.1%
 |
NexoBrid
Enzymatically removes nonviable burn tissue
|
Australian TGA Approval
|
9/25/2025 - Marketing authorization
MediWound Ltd. announced that Australia's Therapeutic Goods Administration (TGA) has granted marketi…
Full Summary
|
VCEL Vericel |
$29.84
-1.4% |
-18.1%
 |
NexoBrid
Enzymatically removes nonviable burn tissue
|
Australian TGA Approval
|
9/25/2025 - Marketing authorization
MediWound Ltd. announced that Australia's Therapeutic Goods Administration (TGA) has granted marketi…
Full Summary
|
ANEB Anebulo Pharmaceuticals |
$2.44
-0.4% |
-12.4%
 |
Selonabant
for Acute Cannabis-Induced Toxicity
|
Phase 1
|
9/25/2025 - Dose Update
Anebulo Pharmaceuticals, Inc announces the first subjects dosed in its Phase 1 single ascending dos…
Full Summary
|
VRTX Vertex Pharmaceuticals |
$381.87
+1.4% |
-1.4%
 |
inaxaplin
APOL1-mediated kidney disease
|
|
9/25/2025 - Provided Update
Vertex Pharmaceuticals Incorporated announced several important advancements across its programs i…
Full Summary
|
VNDA Vanda Pharmaceuticals |
$4.83
-1.4% |
+3.4%
 |
HETLIOZ
For treat jet lag disorder
|
|
9/25/2025 - Publication
Vanda Pharmaceuticals Inc. announced the publication of an article titled "Melatonin agonist tasime…
Full Summary
|
TLSA Tiziana Life Sciences |
$2.07
+5.1% |
+8.9%
|
TZLS-501
A Fully Human anti-IL-6 receptor Monoclonal Antibody
|
|
9/25/2025 - Provided Update
Tiziana Life Sciences, Ltd announces it will advance its second asset, a fully human anti-IL-6 recep…
Full Summary
|
NTLA Intellia Therapeutics |
$16.61
-6.5% |
+46.2%
 |
nex-z
For Transthyretin (ATTR) Amyloidosis with Polyneuropathy
|
|
9/25/2025 - Data
Intellia Therapeutics, announced longer-term follow-up data from the ongoing Phase 1 study of invest…
Full Summary
|
AZN AstraZeneca |
$73.53
-2.4% |
-8.1%
 |
ENHERTU® (fam-trastuzumab deruxtecan-nxki)
For the treatment of adult patients with unresectable or metastatic HER2 positive
|
sBLA Priority Review
|
9/24/2025 - FDA Accepted
AstraZeneca and Daiichi Sankyo announced that supplemental Biologics License Application (sBLA) fo…
Full Summary
|
BNR Burning Rock Biotech |
$9.11
|
+2.2%
 |
Capivasertib
in Breast Cancer
|
MHLW Approval
|
9/24/2025 - Approved
Riken Genesis Co., Ltd. and Burning Rock Biotech Limited announced that the OncoGuide™ OncoScreen™ P…
Full Summary
|
CDTX Cidara Therapeutics |
$84.76
-4.3% |
+26.6%
 |
CD388
Universal Prevention and Treatment of Influenza
|
Phase 3
|
9/24/2025 - Provided Update
Cidara Therapeutics, Inc. announced updates to its planned Phase 3 registrational trial of CD388 fo…
Full Summary
|
FGEN FibroGen |
$12.24
-1.1% |
+18.3%
 |
FG-3246
In Patients with Metastatic Castration-Resistant Prostate Cancer
|
Phase 2
|
9/24/2025 - Initiation
FibroGen, announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a…
Full Summary
|
ACAD ACADIA Pharmaceuticals |
$21.21
-0.2% |
-17.5%
 |
ACP-101
For the treatment of hyperphagia in Prader-Willi syndrome (PWS).
|
Phase 3
|
9/24/2025 - Top-line results
Acadia Pharmaceuticals Inc. announced top-line results from the Phase 3 COMPASS PWS trial evaluati…
Full Summary
|
SMMT Summit Therapeutics |
$20.26
-1.2% |
-24.9%
 |
Ivonescimab
For Lung cancer
|
Phase 3
|
9/24/2025 - Data
Summit Therapeutics Inc announced that data from the Phase III HARMONi-6 trial, conducted in China…
Full Summary
|
BIIB Biogen |
$135.67
-1.5% |
-0.8%
 |
Lecanemab (BAN2401)
Anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD)
|
Australian TGA Approval
|
9/24/2025 - Approved
Eisai Co. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has…
Full Summary
|
COCH Envoy Medical |
$0.85
+2.8% |
-27.3%
 |
Acclaim
for Breakthrough Hearing Device
|
|
9/24/2025 - Provided Update
Envoy Medical® Inc announced it is scaling its commercialization planning for the company's breakthr…
Full Summary
|
NRXP NRx Pharmaceuticals |
$2.91
-2.7% |
+10.6%
 |
KETAFREE™
preservative-free ketamine product
|
|
9/24/2025 - Provided Update
NRx Pharmaceuticals, announced that it was notified yesterday by the United States Food and Drug Ad…
Full Summary
|
HRMY Harmony Biosciences |
$27.04
+1.0% |
-27.3%
 |
ZYN002
In Fragile X Syndrome
|
Phase 3
|
9/24/2025 - Top-line results
Harmony Biosciences Holdings, Inc announced topline results from its Phase 3 registrational clinica…
Full Summary
|
CLRB Cellectar Biosciences |
$5.75
-0.5% |
+20.8%
 |
CLR 125
For the treatment of relapsed TNBC.
|
Phase 1b
|
9/24/2025 - Provided Update
Cellectar Biosciences, Inc. have entered into an agreement whereby Evestia will provide Cellectar w…
Full Summary
|
AKTX Akari Therapeutics |
$1.12
+0.9% |
+30.2%
 |
AR-V7
for the treatment of tumors fueled by alternative splicing-drivers, such as the Androgen Receptor splice variant 7 (AR-V7) in prostate cancer.
|
|
9/24/2025 - Preclinical Data
Akari Therapeutics announced key preclinical data demonstrating the potential of its novel antibody…
Full Summary
|
SNY Sanofi |
$45.07
-2.9% |
-10.4%
 |
SAR446268
for the treatment of non-congenital myotonic dystrophy type 1
|
Fast Track
|
9/23/2025 - Designation Grant
Sanofi announced that The US Food and Drug Administration (FDA) has granted fast track designation …
Full Summary
|
ABBV AbbVie |
$218.23
-0.8% |
+4.7%
 |
SKINVIVE
Advancing Global Skin Quality
|
|
9/23/2025 - Roll Out
Allergan Aesthetics, an AbbVie company announced the roll-out of SKINVIVE by JUVÉDERM® in 35 additi…
Full Summary
|
BMY Bristol Myers Squibb |
$43.45
-1.6% |
-8.0%
|
iberdomide
Relapsed or Refractory Multiple Myeloma
|
Phase 3
|
9/23/2025 - evaluation
Bristol Myers Squibb announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an inve…
Full Summary
|
ELAN Elanco Animal Health |
$18.93
+1.0% |
+5.7%
 |
Zenrelia
Treatment for canine allergic itch and inflammation
|
|
9/23/2025 - Provided Update
Elanco Animal Health nnounced important updates to the U.S. Zenrelia label, following the Food and …
Full Summary
|
MCRB Seres Therapeutics |
$18.90
-2.5% |
-2.3%
 |
SER-155
Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
|
Phase 2
|
9/23/2025 - Feedback
Seres Therapeutics, announced receipt of additional constructive feedback from the U.S. Food and Dr…
Full Summary
|
ATAI atai Life Sciences |
$5.17
-5.8% |
+7.0%
 |
BPL-003
In Patients With Treatment Resistant Depression
|
|
9/23/2025 - Positive Data
atai Life Sciences announced positive data from a proof-of-concept study investigating a two-dose in…
Full Summary
|
SRRK Scholar Rock |
$34.49
+2.3% |
+2.1%
 |
Apitegromab
Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
|
|
9/23/2025 - Complete Response Letter
Scholar Rock announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Respo…
Full Summary
|
MRNA Moderna |
$24.61
-4.9% |
-0.5%
 |
COVID-19 vaccine
Covid-19
|
|
9/23/2025 - Positive Data
Moderna, Inc. announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXS…
Full Summary
|
SNSE Sensei Biotherapeutics |
$8.77
-2.8% |
+8.3%
 |
Solnerstotug
in PD-(L)1 Resistant Tumors
|
|
9/23/2025 - Provided Update
Sensei Biotherapeutics, Inc. announced that it will host a virtual key opinion leader (KOL) event on…
Full Summary
|
ICU SeaStar Medical |
$0.61
-50.9% |
-32.3%
 |
QUELIMMUNE
For the treatment of children weighing 10 kilograms or more with acute kidney injury (AKI) and sepsis or septic condition requiring kidney replacement therapy (KRT).
|
|
9/23/2025 - Results
SeaStar Medical Holding Corporation announced today that preliminary results from the SAVE Surveill…
Full Summary
|
TVGN Tevogen Bio |
$0.79
+1.5% |
-14.8%
 |
TVGN 489
To treat acute, high-risk Covid-19 patients.
|
|
9/23/2025 - Provided Update
Tevogen today highlights emerging scientific evidence linking persistent viral reservoirs to Long CO…
Full Summary
|
VERU Veru |
$3.59
+4.1% |
+3.5%
 |
Enobosarm
ER+/HER2- breast cancer
|
|
9/23/2025 - FDA Meeting
Veru Inc announced a successful meeting with FDA providing regulatory clarity for enobosarm, a selec…
Full Summary
|
NBIX Neurocrine Biosciences |
$140.89
-3.9% |
+3.0%
 |
INGREZZA (Valbenazine)
Tardive Dyskinesia
|
|
9/23/2025 - New Data
Neurocrine Biosciences, announced new data from a post-hoc analysis of the Phase 4 KINECT-PRO™ ope…
Full Summary
|
BIIB Biogen |
$135.67
-1.5% |
-0.8%
|
nusinersen
In Treatment of spinal muscular atrophy (SMA).
|
|
9/23/2025 - Complete Response Letter
Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Le…
Full Summary
|
MBX MBX Biosciences |
$17.33
-13.8% |
+12.8%
 |
canvuparatide
for Hypoparathyroidism
|
Phase 2
|
9/22/2025 - Primary Endpoint
MBX Biosciences, Inc. announced once-weekly canvuparatide achieved the primary endpoint with statis…
Full Summary
|
IONS Ionis Pharmaceuticals |
$62.97
-1.5% |
+49.3%
 |
Zilganersen
for the treatment of children and adults Alexander disease (AxD).
|
|
9/22/2025 - Top-line results
Ionis Pharmaceuticals, Inc announced positive topline results from the pivotal study of zilganersen…
Full Summary
|
IONS Ionis Pharmaceuticals |
$62.97
-1.5% |
+49.3%
|
Zilganersen
for the treatment of children and adults Alexander disease (AxD).
|
Target date: Q1 2026
|
9/22/2025 - NDA Filing
Ionis Pharmaceuticals, Inc announced that NDA submission planned in Q1 2026
Full Summary
|
EXAS Exact Sciences |
$53.68
+1.1% |
+16.4%
 |
Cologuard test
For CRC screening
|
|
9/22/2025 - Provided Update
Exact Sciences Corp. a leading provider of cancer screening and diagnostic tests, is teaming up wit…
Full Summary
|
INSM Insmed |
$135.59
-3.8% |
+2.6%
 |
Treprostinil Palmitil Inhalation Powder (TPIP)
Pulmonary arterial hypertension (PAH)
|
|
9/22/2025 - Abstract
Insmed Incorporated announced that it will present seven abstracts from across its late-stage portf…
Full Summary
|
BBIO BridgeBio Pharma |
$49.00
-3.3% |
+0.3%
 |
Acoramidis (ATTRibute-CM)
Symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM)
|
|
9/22/2025 - Late Breaking Presentation
BridgeBio Pharma, Inc. announced today that one late breaking clinical trials oral presentation, o…
Full Summary
|
NTLA Intellia Therapeutics |
$16.61
-6.5% |
+46.2%
|
nex-z
For Transthyretin (ATTR) Amyloidosis with Polyneuropathy
|
Phase 1
|
9/22/2025 - Data
Intellia Therapeutics, announced that longer-term data from the ongoing Phase 1 trial of investiga…
Full Summary
|
GOSS Gossamer Bio |
$2.78
-7.0% |
+9.9%
 |
seralutinib
Treatment of Pulmonary Arterial Hypertension
|
|
9/22/2025 - Presentation
Gossamer Bio, Inc announced that five scientific presentations related to seralutinib will be prese…
Full Summary
|
JAZZ Jazz Pharmaceuticals |
$127.80
-1.4% |
+2.2%
 |
Xywav
Idiopathic hypersomnia
|
Phase 4
|
9/22/2025 - New Data
Jazz Pharmaceuticals plc announced new real-world evidence and Phase 4 data reinforcing the value o…
Full Summary
|
ACST Acasti Pharma |
$3.11
|
|
GTX-104
IV infusion for patients experiencing Subarachnoid Hemorrhage (SAH)
|
Phase 3
|
9/22/2025 - Results
Grace Therapeutics, Inc. announced that results from its Pivotal Phase 3 STRIVE-ON Safety Trial of G…
Full Summary
|
ADVM Adverum Biotechnologies |
$4.31
-0.7% |
+36.4%
 |
Ixo-vec
For the Treatment of Wet AMD
|
Phase 3
|
9/22/2025 - Provided Update
Adverum Biotechnologies, Inc announced it has notified sites that it plans to complete screening i…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.30
-3.7% |
-6.5%
 |
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
|
Phase 1
|
9/22/2025 - Top-line results
MIRA Pharmaceuticals, Inc announced topline results from the single ascending dose (SAD) portion o…
Full Summary
|
ALLR Allarity Therapeutics |
$1.54
-5.5% |
+7.7%
 |
stenoparib (2X-121)
ovarian cancer
|
Phase 2
|
9/22/2025 - Provided Update
Allarity Therapeutics, Inc. presented new and updated clinical data from the ongoing Phase 2 clinica…
Full Summary
|
ANIX Anixa Biosciences |
$3.38
-1.7% |
+13.0%
 |
alpha-lactalbumin
In high risk operable triple negative breast cancer
|
Phase 1
|
9/22/2025 - Results
Anixa Biosciences, Inc announced that final results from the Phase 1 clinical trial of its breast c…
Full Summary
|
IMMP Prima BioMed |
$1.68
-0.6% |
-0.6%
 |
eftilagimod alpha
For cancer and autoimmune disease
|
Phase 2
|
9/22/2025 - evaluation
Immutep Limited announces the initiation of an investigator-initiated Phase II trial evaluating neoa…
Full Summary
|
ACHV Achieve Life Sciences |
$2.97
-3.6% |
-4.8%
 |
cytisinicline
For the treatment of nicotine dependence
|
|
9/22/2025 - Publication
Achieve Life Sciences, Inc. announced the publication of new data in Thorax demonstrating that cyti…
Full Summary
|
CRSP CRISPR Therapeutics |
$60.32
-1.2% |
+9.9%
 |
SRSD107
for Thromboembolic Disorders
|
Phase 2
|
9/22/2025 - Dose Update
CRISPR Therapeutics announced that the first patient has been dosed in a Phase 2 clinical trial of …
Full Summary
|
ACTU Actuate Therapeutics |
$6.65
-5.3% |
-18.8%
 |
elraglusib
In relapsed/refractory Ewing Sarcoma (r/r EWS).
|
|
9/22/2025 - Provided Update
Actuate Therapeutics, Inc. announced a corporate update on the regulatory path for elraglusib in pan…
Full Summary
|
NBIX Neurocrine Biosciences |
$140.89
-3.9% |
+3.0%
|
NBI-1065845
In Adults with Major Depressive Disorder
|
Phase 2
|
9/22/2025 - Presentation
Neurocrine Biosciences, announced the presentation of new data from the Phase 2 SAVITRI™ study, whi…
Full Summary
|
CELC Celcuity |
$51.94
-3.8% |
+5.0%
 |
VIKTORIA-1
in patients with HR+/HER2-/PIK3CA wild-type advanced breast cancer
|
|
9/22/2025 - Abstract
Celcuity Inc. announced that a late breaking abstract reporting clinical data from the Phase 3 VIKT…
Full Summary
|
SNY Sanofi |
$45.07
-2.9% |
-10.4%
|
Tolebrutinib
Bruton’s tyrosine kinase (BTK) inhibitor
|
Target date: December 28, 2025
|
9/22/2025 - Target action date
Sanofi SA announced that the U.S. Food and Drug Administration (FDA) extended the review date for ne…
Full Summary
|
CORT Corcept Therapeutics |
$82.73
-1.3% |
+18.9%
 |
Relacorilant
Recurrent Platinum-Resistant Ovarian Cancer
|
Phase 3
|
9/22/2025 - New Data
Corcept Therapeutics Incorporated will present new data from its pivotal Phase 3 ROSELLA trial of re…
Full Summary
|
LXRX Lexicon Pharmaceuticals |
$1.34
+0.8% |
+17.5%
 |
sotagliflozin
INPEFA™ (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1).
|
|
9/22/2025 - Additional data
Lexicon Pharmaceuticals, Inc. announced an update to the previous submission of additional clinical …
Full Summary
|
DCTH Delcath Systems |
$10.86
-1.5% |
-2.3%
 |
CHOPIN
for percutaneous hepatic perfusion with melphalan in patients with metastatic uveal melanoma.
|
Phase 2
|
9/22/2025 - Oral presentation
Delcath Systems, Inc announced the acceptance of an oral presentation on results from the investigat…
Full Summary
|
CCCC C4 Therapeutics |
$2.19
-9.5% |
-14.8%
 |
cemsidomide
IKZF1/3 Degrader
|
Phase 1
|
9/20/2025 - Data Presentation
C4 Therapeutics, Inc. today presented data from the Phase 1 clinical trial of cemsidomide, an orally…
Full Summary
|
TEVA Teva Pharmaceutical Industries |
$18.43
-4.4% |
+1.4%
 |
TEV-749
In adult patients with schizophrenia
|
|
9/20/2025 - Presentation
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the presenta…
Full Summary
|
TEVA Teva Pharmaceutical Industries |
$18.43
-4.4% |
+1.4%
|
AUSTEDO (deutetrabenazine)
Tardive dyskinesia and a review of clinical outcome measures in schizophrenia
|
|
9/20/2025 - Presentation
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd announced the presenta…
Full Summary
|
MRK Merck & Co., Inc. |
$77.70
-2.5% |
-8.7%
|
KEYTRUDA®(pembrolizumab)
For the treatment of patients with locally advanced or metastatic urothelial carcinoma
|
EMA
|
9/19/2025 - Positive Opinion
Merck announced that announced that the European Medicines Agency's Committee for Medicinal Products…
Full Summary
|
MRK Merck & Co., Inc. |
$77.70
-2.5% |
-8.7%
|
ENFLONSIA™
In Infants Born During or Entering Their First RSV Season
|
EMA
|
9/19/2025 - Recommended Approval
Merck announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European…
Full Summary
|
SNDX Syndax Pharmaceuticals |
$15.03
+0.1% |
-5.2%
 |
Revumenib
Relapsed/Refractory KMT2Ar Acute Leukemia
|
|
9/19/2025 - Provided Update
Syndax Pharmaceuticals announced that the National Comprehensive Cancer Network® (NCCN®) Clinical P…
Full Summary
|
KALV KalVista Pharmaceuticals |
$12.10
-6.4% |
-8.1%
 |
sebetralstat
Therapy for hereditary angioedema (HAE).
|
EMA
|
9/19/2025 - Approved
KalVista Pharmaceuticals, Inc announced that the European Commission (EC) and Swiss Agency for Ther…
Full Summary
|
IONS Ionis Pharmaceuticals |
$62.97
-1.5% |
+49.3%
|
Olezarsen (Formerly IONIS-APOCIII-L)
Severe hypertriglyceridemia
|
|
9/19/2025 - Presentation
Ionis Pharmaceuticals, Inc announced that TRYNGOLZA® (olezarsen) has been approved in the European …
Full Summary
|
SABS SAB Biotherapeutics |
$2.10
-2.8% |
-2.8%
 |
SAB-142
Anti-thymocyte hpAB therapeutic
|
|
9/19/2025 - Highlights
SAB Biotherapeutics, Inc. today highlighted multiple presentations made at the 61st Annual Meeting o…
Full Summary
|
UTHR United Therapeutics |
$425.42
-3.0% |
+37.6%
 |
Tyvaso (Treprostinil)
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
|
|
9/19/2025 - Provided Update
United Therapeutics Corporation announced today that it will host a webcast to review data from the…
Full Summary
|
VRCA Verrica Pharmaceuticals |
$4.09
-1.9% |
-31.5%
 |
YCANTH™ (cantharidin)
For molluscum contagiosum, which is primarily a pediatric disease.
|
MHLW Approval
|
9/19/2025 - Approved
Verrica Pharmaceuticals Inc. announced that its development partner, Torii Pharmaceutical Co. Ltd. …
Full Summary
|
JNJ Johnson & Johnson |
$177.71
+0.6% |
+0.6%
 |
TECVAYLI
For patients with newly diagnosed multiple myeloma
|
|
9/19/2025 - Provided Update
Johnson & Johnson announced that an investigational immune-based induction regimen with TECVAYLI® (…
Full Summary
|
GNFT GENFIT |
$3.53
-2.8% |
-13.9%
 |
VS-01
in ACLF (Acute-on-Chronic Liver Failure)
|
|
9/19/2025 - Discontinue
GENFIT announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver Fail…
Full Summary
|
MBX MBX Biosciences |
$17.33
-13.8% |
+12.8%
|
canvuparatide
for Hypoparathyroidism
|
Phase 2
Target date: September 22, 2025
|
9/19/2025 - Top-line results
MBX Biosciences, Inc. announced that it will provide topline results from its Phase 2 clinical tria…
Full Summary
|
JNJ Johnson & Johnson |
$177.71
+0.6% |
+0.6%
|
Guselkumab
For Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis
|
|
9/19/2025 - FDA approved
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a subcut…
Full Summary
|
MRK Merck & Co., Inc. |
$77.70
-2.5% |
-8.7%
|
KEYTRUDA QLEX™
Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
|
|
9/19/2025 - FDA approved
Merck announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™(pembrol…
Full Summary
|
GLSI Greenwich LifeSciences |
$10.42
-4.8% |
-12.7%
 |
GLSI-100
Breast cancer recurrences
|
|
9/18/2025 - Provided Update
Greenwich LifeSciences, In announced the expansion of FLAMINGO-01 clinical trial to Ireland.
Full Summary
|
AZN AstraZeneca |
$73.53
-2.4% |
-8.1%
|
AIRSUPRA
For asthma
|
Phase 3b
|
9/18/2025 - Provided Update
Astrazeneca announced that The BATURA Phase IIIb trial, which evaluated severe exacerbation risk red…
Full Summary
|
TRVI Trevi Therapeutics |
$8.46
-0.1% |
+14.0%
 |
Haduvio (nalbuphine ER).
IPF Chronic Cough
|
Phase 2a
|
9/18/2025 - Data
Trevi Therapeutics, announced that data from the Phase 2a RIVER trial of nalbuphine ER for the trea…
Full Summary
|
GANX Gain Therapeutics |
$1.73
-0.6% |
-9.9%
 |
GT-02287
For Parkinson Disease
|
Phase 1b
|
9/18/2025 - Study Expansion
Gain Therapeutics, Inc. announced the start of the Phase 1b extension study allowing participants …
Full Summary
|
NTLA Intellia Therapeutics |
$16.61
-6.5% |
+46.2%
|
onvo-z
hereditary angioedema
|
Phase 3
|
9/18/2025 - Enrollment Update
Intellia Therapeutics, announced it has completed enrollment in the global Phase 3 HAELO study of l…
Full Summary
|
NTLA Intellia Therapeutics |
$16.61
-6.5% |
+46.2%
|
onvo-z
hereditary angioedema
|
Target date: H1 2026
|
9/18/2025 - Top-line data
Intellia Therapeutics, announced that Topline data are expected in the first half of 2026.
Full Summary
|
PHIO Phio Pharmaceuticals |
$2.20
-1.3% |
+7.8%
 |
PH-762 (INTASYL)
Murine colorectal cancer
|
|
9/18/2025 - Presentation
Phio Pharmaceuticals Corp announced that Phio Pharmaceuticals is a presenting company at the Life S…
Full Summary
|
TNXP Tonix Pharmaceuticals |
$24.00
-2.8% |
-29.4%
 |
TNX-102 SL
Fibromyalgia
|
FDA Type B Meeting
|
9/18/2025 - FDA Meeting
Tonix Pharmaceuticals announced the successful completion of a Type B Pre-Investigational New Drug…
Full Summary
|
ACST Acasti Pharma |
$3.11
|
|
GTX-104
IV infusion for patients experiencing Subarachnoid Hemorrhage (SAH)
|
|
9/18/2025 - Provided Update
Grace Therapeutics, Inc announced that the U.S. Patent and Trademark Office has issued a U.S. Paten…
Full Summary
|
VRTX Vertex Pharmaceuticals |
$381.87
+1.4% |
-1.4%
|
CASGEVY
For the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
|
|
9/18/2025 - Provided Update
Vertex Pharmaceuticals announced today a reimbursement agreement with the Italian Medicines Agency (…
Full Summary
|
NKTR Nektar Therapeutics |
$55.62
-7.8% |
+93.3%
 |
Rezpegaldesleukin
For the treatment of atopic dermatitis.
|
Phase 2b
|
9/18/2025 - New Data
Nektar Therapeutics announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleuk…
Full Summary
|
PDSB PDS Biotechnology |
$1.03
-2.8% |
-20.2%
 |
VERSATILE-002
Treatment of recurrent or metastatic human papillomavirus (HPV)16-positive head and neck cancer.
|
Phase 2
|
9/18/2025 - Provided Update
PDS Biotechnology announced details of a sub-analysis of the cohort of patients with low PD-L1 expr…
Full Summary
|
INCY Incyte |
$81.66
-3.0% |
-2.8%
 |
Opzelura® (Ruxolitinib)
treatment of mild to moderate atopic dermatitis
|
|
9/18/2025 - FDA approved
Incyte y announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura® (ruxoliti…
Full Summary
|
ORKA Oruka Therapeutics |
$15.05
-1.4% |
+1.6%
 |
ORKA-001
Inhibitor IL-23p19
|
Phase 1
|
9/17/2025 - Interim Data
Oruka Therapeutics announced interim data from its Phase 1 trial of ORKA-001, the Company's long-act…
Full Summary
|
IPHA Innate Pharma |
$1.82
-1.1% |
-11.7%
 |
Lacutamab
Treatment of patients with relapsed or refractory Sézary syndrome
|
|
9/17/2025 - Provided Update
Innate Pharma SA provided Business Update
Full Summary
|
INCY Incyte |
$81.66
-3.0% |
-2.8%
|
povorcitinib
AK1 inhibitor
|
Phase 3
|
9/17/2025 - Interim Data
Incyte announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54…
Full Summary
|
ARQT Arcutis Biotherapeutics |
$16.73
-3.3% |
+5.7%
 |
ZORYVE™ (roflumilast)
Inhibitor of phosphodiesterase-4 (PDE4)
|
|
9/17/2025 - New Data
Arcutis Biotherapeutics, Inc. announced that new data on ZORYVE (roflumilast) efficacy across three …
Full Summary
|
CLDX Celldex Therapeutics |
$25.25
-1.4% |
+16.1%
 |
Barzolvolimab
For Prurigo Nodularis
|
Phase 2
|
9/17/2025 - New Data
Celldex announced today new data demonstrating rapid and strong efficacy regardless of baseline immu…
Full Summary
|
TNXP Tonix Pharmaceuticals |
$24.00
-2.8% |
-29.4%
|
TNX-4800
Lyme Disease
|
|
9/17/2025 - Provided Update
Tonix Pharmaceuticals announced the in-licensing of worldwide rights to TNX-4800 (formerly known as…
Full Summary
|
ROIV Roivant Sciences |
$14.96
+1.8% |
+26.4%
 |
Brepocitinib
Systemic Lupus Erythematosus
|
Phase 3
|
9/17/2025 - Positive Results
Roivant and Priovant Therapeutics today announced positive results from the Phase 3 VALOR study eval…
Full Summary
|
KYMR Kymera Therapeutics |
$53.74
+2.4% |
+22.5%
 |
KT-621
A potential oral treatment for asthma and other TH2 respiratory diseases.
|
Phase 1
|
9/17/2025 - Positive Results
Kymera Therapeutics announced that the positive results from the Phase 1 healthy volunteer clinical …
Full Summary
|
